These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

635 related articles for article (PubMed ID: 31574522)

  • 21. Closure of patent foramen ovale or medical therapy alone for secondary prevention of cryptogenic cerebrovascular events.
    Fortuni F; Crimi G; Leonardi S; Angelini F; Raisaro A; Lanzarini LF; Oltrona Visconti L; Ferrario M; De Ferrari GM
    J Cardiovasc Med (Hagerstown); 2018 Jul; 19(7):373-381. PubMed ID: 29708911
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Meta-analysis of Randomized Controlled Trials on Patent Foramen Ovale Closure Versus Medical Therapy for Secondary Prevention of Cryptogenic Stroke.
    Smer A; Salih M; Mahfood Haddad T; Guddeti R; Saadi A; Saurav A; Belbase R; Ayan M; Traina M; Alla V; Del Core M
    Am J Cardiol; 2018 Jun; 121(11):1393-1399. PubMed ID: 29680170
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Percutaneous Closure of Patent Foramen Ovale in Patients with Cryptogenic Stroke - An Updated Comprehensive Meta-Analysis.
    Sitwala P; Khalid MF; Khattak F; Bagai J; Bhogal S; Ladia V; Mukherjee D; Daggubati R; Paul TK
    Cardiovasc Revasc Med; 2019 Aug; 20(8):687-694. PubMed ID: 30282597
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Patent foramen ovale closure versus medical therapy after cryptogenic stroke: An updated meta-analysis of all randomized clinical trials.
    Kheiri B; Abdalla A; Osman M; Ahmed S; Hassan M; Bachuwa G
    Cardiol J; 2019; 26(1):47-55. PubMed ID: 29512097
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Patent foramen ovale closure versus medical therapy for prevention of recurrent cryptogenic embolism: updated meta-analysis of randomized clinical trials.
    Alushi B; Lauten A; Cassese S; Colleran R; Schüpke S; Rai H; Schunkert H; Meier B; Landmesser U; Kastrati A
    Clin Res Cardiol; 2018 Sep; 107(9):788-798. PubMed ID: 29644412
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Meta-Analysis Comparing Patent Foramen Ovale Closure Versus Medical Therapy to Prevent Recurrent Cryptogenic Stroke.
    Ando T; Holmes AA; Pahuja M; Javed A; Briasoulis A; Telila T; Takagi H; Schreiber T; Afonso L; Grines CL; Bangalore S
    Am J Cardiol; 2018 Mar; 121(5):649-655. PubMed ID: 29306484
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Patent Foramen Ovale Closure or Antiplatelet Therapy for Cryptogenic Stroke.
    Søndergaard L; Kasner SE; Rhodes JF; Andersen G; Iversen HK; Nielsen-Kudsk JE; Settergren M; Sjöstrand C; Roine RO; Hildick-Smith D; Spence JD; Thomassen L;
    N Engl J Med; 2017 Sep; 377(11):1033-1042. PubMed ID: 28902580
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Patent Foramen Ovale and Cryptogenic Stroke or Transient Ischemic Attack: To Close or Not to Close? A Systematic Review and Meta-Analysis.
    Lattanzi S; Brigo F; Cagnetti C; Di Napoli M; Silvestrini M
    Cerebrovasc Dis; 2018; 45(5-6):193-203. PubMed ID: 29649819
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Systematic review of percutaneous closure versus medical therapy in patients with cryptogenic stroke and patent foramen ovale.
    Spencer FA; Lopes LC; Kennedy SA; Guyatt G
    BMJ Open; 2014 Mar; 4(3):e004282. PubMed ID: 24607561
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Patent Foramen Ovale Closure for Secondary Prevention of Cryptogenic Stroke: Updated Meta-Analysis of Randomized Clinical Trials.
    Vaduganathan M; Qamar A; Gupta A; Bajaj N; Golwala HB; Pandey A; Bhatt DL
    Am J Med; 2018 May; 131(5):575-577. PubMed ID: 29229471
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Percutaneous closure of patent foramen ovale for cryptogenic stroke: a meta-analysis of randomized controlled trials.
    Kwong JS; Lam YY; Yu CM
    Int J Cardiol; 2013 Oct; 168(4):4132-8. PubMed ID: 23890879
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Closure versus Medical Therapy for Patent Foramen Ovale in Patients with Cryptogenic Stroke: An Updated Meta-Analysis of Randomized Controlled Trials.
    Qiu B; Cai Y; Wang D; Lin J; Fan Y
    J Stroke Cerebrovasc Dis; 2018 Dec; 27(12):3463-3472. PubMed ID: 30185398
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Patent foramen ovale closure versus medical therapy for cryptogenic stroke: An updated meta-analysis.
    Xu HB; Zhang H; Qin Y; Xue F; Xiong G; Yang L; Bai H; Wu J
    J Neurol Sci; 2018 Jul; 390():139-149. PubMed ID: 29801875
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Percutaneous closure of patent foramen ovale in patients with cryptogenic embolism: a network meta-analysis.
    Stortecky S; da Costa BR; Mattle HP; Carroll J; Hornung M; Sievert H; Trelle S; Windecker S; Meier B; Jüni P
    Eur Heart J; 2015 Jan; 36(2):120-8. PubMed ID: 25112661
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Patent foramen ovale closure with GORE HELEX or CARDIOFORM Septal Occluder vs. antiplatelet therapy for reduction of recurrent stroke or new brain infarct in patients with prior cryptogenic stroke: Design of the randomized Gore REDUCE Clinical Study.
    Kasner SE; Thomassen L; Søndergaard L; Rhodes JF; Larsen CC; Jacobson J
    Int J Stroke; 2017 Dec; 12(9):998-1004. PubMed ID: 29090661
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predictors of recurrent events in patients with cryptogenic stroke and patent foramen ovale within the CLOSURE I (Evaluation of the STARFlex Septal Closure System in Patients With a Stroke and/or Transient Ischemic Attack Due to Presumed Paradoxical Embolism Through a Patent Foramen Ovale) trial.
    Elmariah S; Furlan AJ; Reisman M; Burke D; Vardi M; Wimmer NJ; Ling S; Chen X; Kent DM; Massaro J; Mauri L;
    JACC Cardiovasc Interv; 2014 Aug; 7(8):913-20. PubMed ID: 25147037
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Percutaneous closure versus medical therapy for stroke with patent foramen Ovale: a systematic review and meta-analysis.
    Zhang XL; Kang LN; Wang L; Xu B
    BMC Cardiovasc Disord; 2018 Mar; 18(1):45. PubMed ID: 29499641
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Transcatheter closure of patent foramen ovale for secondary prevention of ischemic stroke: Quantitative synthesis of pooled randomized trial data.
    Hakeem A; Cilingiroglu M; Katramados A; Boudoulas KD; Iliescu C; Gundogdu B; Marmagkiolis K
    Catheter Cardiovasc Interv; 2018 Nov; 92(6):1153-1160. PubMed ID: 29332308
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Is Patent Foramen Ovale Closure More Effective Than Medical Therapy in Preventing Stroke Recurrence in Patients With Cryptogenic Stroke?: A Critically Appraised Topic.
    Valencia-Sanchez C; Fortuin FD; Sweeney JP; Ingall TJ; Marks LA; Wingerchuk DM; O'Carroll CB
    Neurologist; 2018 Sep; 23(5):175-180. PubMed ID: 30169372
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Patent foramen ovale closure vs medical therapy for stroke prevention: meta-analysis of randomized trials and review of heterogeneity in meta-analyses.
    Udell JA; Opotowsky AR; Khairy P; Silversides CK; Gladstone DJ; O'Gara PT; Landzberg MJ
    Can J Cardiol; 2014 Oct; 30(10):1216-24. PubMed ID: 25154803
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.